Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer

Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer

Interstitial lung disease (ILD) is a serious and potentially fatal adverse event in lung cancer therapy. Nanoparticle albumin-bound paclitaxel (nab-PTX) is a novel, solvent-free formulation of paclitaxel (PTX). Although the incidence of nab-PTX-induced ILD is not clear, it is generally considered th...

Full description

Bibliographic Details
Main Authors: Yuki Nakatani, Aya Nakaya, Takayasu Kurata, Takashi Yokoi, Yuki Takeyasu, Maiko Niki, Kayoko Kibata, Naoko Satsutani, Makoto Ogata, Takayuki Miyara, Shosaku Nomura
Format: Article
Language:English
Published: Karger Publishers 2017-08-01
Series:Case Reports in Oncology
Subjects:
Interstitial lung disease
Nanoparticle albumin-bound paclitaxel
Non-small cell lung cancer
Single-agent treatment
Online Access:http://www.karger.com/Article/FullText/479148

Internet

http://www.karger.com/Article/FullText/479148

Similar Items